Alzheimer's disease (AD) is the most common form of dementia and associated with progressive deposition of amyloid b-peptides (Ab) in the brain. Ab derives by sequential proteolytic processing of the amyloid precursor protein by b-and c-secretases. Rare mutations that lead to amino-acid substitutions within or close to the Ab domain promote the formation of neurotoxic Ab assemblies and can cause early-onset AD. However, mechanisms that increase the aggregation of wild-type Ab and cause the much more common sporadic forms of AD are largely unknown. Here, we show that extracellular Ab undergoes phosphorylation by protein kinases at the cell surface and in cerebrospinal fluid of the human brain. Phosphorylation of serine residue 8 promotes formation of oligomeric Ab assemblies that represent nuclei for fibrillization. Phosphorylated Ab was detected in the brains of transgenic mice and human AD brains and showed increased toxicity in Drosophila models as compared with non-phosphorylated Ab. Phosphorylation of Ab could represent an important molecular mechanism in the pathogenesis of the most common sporadic form of AD.
Introduction
The post-translational modification by phosphorylation has an important role in the regulation of protein activity. Protein kinases that catalyse the phosphorylation reaction mainly exert their activity towards intracellular targets and thereby regulate important physiological and pathophysiological processes, including cellular metabolism, differentiation and proliferation. In addition to intracellular protein kinases, several kinase activities have been demonstrated at the cell surface and in extracellular fluids (Chen et al, 1996; Redegeld et al, 1999) . These ecto-protein kinases phosphorylate cell surface localized as well as extracellular soluble proteins, including proteins of the complement system, coagulation factors and cell adhesion proteins. Several distinct ecto-protein kinases have been characterized and appear to be very similar to intracellular kinases, such as protein kinases (PK) A, C, CK1 and CK2 (Kübler et al, 1989; Walter et al, 1996) . However, the physiological and/or pathophysiological significance of extracellular protein phosphorylation is poorly understood.
Alzheimer's disease (AD) is the most common form of dementia and associated with the progressive accumulation of amyloid b-peptides (Ab) in form of extracellular amyloid plaques in the human brain. Ab derives from the amyloid precursor protein (APP) by proteolytic processing. The sequential cleavage of APP by enzymes called b-and g-secretase leads to secretion of Ab from cells into extracellular fluids (Selkoe, 2001; Mattson, 2004) . Ab peptides could aggregate and form insoluble fibrils that represent major components of extracellular plaques. The role of plaque deposition in the pathogenesis of AD and particularly their neurotoxic properties are currently under debate. However, a close relationship of plaques and impaired dendritic activity supports the critical role of plaques in neurotoxicity (SpiresJones et al, 2007; Koffie et al, 2009; Meyer-Luehmann et al, 2009) . Notably, recent research also strongly supports an important role of small oligomeric forms of Ab in neurotoxicity and degeneration (Yankner, 1996; Chiti and Dobson, 2006; Haass and Selkoe, 2007; Selkoe, 2008) .
A critical role of Ab in the pathogenesis of AD is strongly supported by gene mutations that cause early-onset familial forms of the disease. Such mutations have been identified in the APP gene itself and in presenilin 1 and 2. Importantly, all mutations identified in the different genes commonly lead to early deposition of extracellular plaques likely by increasing the generation and/or aggregation of Ab (Nilsberth et al, 2001; Kennedy et al, 2003; Tanzi and Bertram, 2005; Hori et al, 2007; Di et al, 2009) .
The aggregation of Ab and other proteins that cause neurodegenerative and other diseases appears to follow similar pathways and depends on the formation of small soluble nuclei that could act as seeds and thereby promote rapid fibril growth (Harper and Lansbury, 1997; Soto and Estrada, 2008) . Thus, the assembly of monomeric proteins or peptides into smaller oligomeric structures is the rate-limiting step in fibril formation. Certain mutations within the Ab domain that cause early-onset AD (EOAD) promote formation of oligomeric assemblies and fibrillization (Kirkitadze et al, 2001; Murakami et al, 2003; Tomiyama et al, 2010) . However, such disease causing mutations in the Ab domain are very rare and only account for a few cases of EOAD.
Mechanisms that drive formation of oligomeric nuclei of wild-type (WT) Ab and thereby might promote the pathogenesis of AD remain largely unclear. However, studies on pyroglutamate-modified variants of Ab suggest a critical role of N-terminal modification in the aggregation process (Schilling et al, 2008) . Whether other post-translational modifications could affect Ab deposition is unknown. Here, we sought to determine whether extracellular Ab could be phosphorylated by ecto-protein kinase in the brain and its pathophysiological implications.
Results

Phosphorylation of extracellular Ab by ecto-PKA
To test the phosphorylation of extracellular Ab, primary cultures of mouse cortical neurons were incubated with synthetic Ab and [g-32 P]ATP. Ab was readily phosphorylated ( Figure 1A) . No radiolabelling was observed in the absence of cells (data not shown), indicating the presence of an ectoprotein kinase at the surface of neurons that phosphorylates Ab ( Figure 1A ). Ab was not detected in the corresponding cell lysates, suggesting that Ab was not internalized and phosphorylated by intracellular kinases under the experimental conditions ( Figure 1B) . In silico analysis revealed serine residue 8 (Ser8) within a potential recognition motif (R-x-x-S) for PKA ( Figure 1C ). Phosphorylation of extracellular Ab was significantly reduced in the presence of the selective PKA inhibitor H-89, indeed indicating an involvement of an extracellular PKA activity. However, cAMP did not further stimulate Ab phosphorylation ( Figure 1D and E). These findings are consistent with a selective secretion of PKA catalytic subunits and the absence of extracellular regulatory b-subunits that has been demonstrated previously in tumour cells (Cho et al, 2000b) .
To directly demonstrate phosphorylation of Ab by PKA, different variants of Ab were incubated with purified PKA in vitro. PKA readily phosphorylated Ab40 or Ab42, the two major variants in the human brain. Further in vitro assays using truncated variants, including Ab1-16, Ab17-40 and prephosphorylated Ab variants, confirmed the selective phosphorylation of Ab by PKA at Ser8 (Figure 1F, G and H; Supplementary Figure S1A and B) . Phosphorylation of Ab was detected at low nanomolar concentrations of ATP (Supplementary Figure S1C and D) , indicating that physiological concentrations of extracellular ATP in biological fluids allow phosphorylation of Ab in vivo.
To assess the presence of extracellular PKA activity in the human brain, we performed ex vivo phosphorylation assays with human cerebrospinal fluid (CSF). CSF was incubated with [g-32 P]ATP and histone, a cognate substrate for PKA. Notably, histone was efficiently phosphorylated by endogenous kinase activity in the CSF. Since this phosphorylation was strongly reduced by H-89, these data confirm the presence of an extracellular PKA-like activity in human CSF ( Figure 1I ). Importantly, human CSF also contained Ab phosphorylating activity that could be efficiently inhibited by several PKAspecific inhibitors (KT5720, PKI and H-89) or by immunodepletion of PKA ( Figure 1J) . These combined data demonstrate the presence of extracellular PKA in the human brain that could phosphorylate Ab at Ser8.
Phosphorylation of Ab promotes its aggregation
We next assessed whether the phosphorylation of Ser8 affects the aggregation of Ab. Phosphorylated Ab (pAb) and nonphosphorylated Ab (npAb) were incubated and aggregation was monitored by Thioflavin T (Figure 2A ) or Congo Red assays (Supplementary Figure S2) . npAb showed the expected behaviour in aggregation with a pronounced lag phase before rapid fibril growth in both assays (Figure 2A ; Supplementary Figure S2) . Notably, pAb showed significantly increased aggregation as compared with npAb. However, both variants formed characteristic fibrils highly similar in morphology and size at the end point of this assay ( Figure 2B ). The analysis of aggregation kinetics revealed that npAb takes about five times longer to exit the lag phase than pAb (Supplementary Table SI) . It is also interesting to note that, despite the remarkably faster aggregation of pAb than npAb, their apparent rate constant values 'k' were very similar. Altogether, these data suggest that the higher rate of aggregation for pAb is predominantly caused by a more efficient nucleation, during which a higher number of small aggregates are formed. To prove increased oligomer formation of pAb, samples were separated by SDS-PAGE and Ab variants detected by western blotting (WB). As compared with npAb, pAb formed SDS-resistant low-molecular weight oligomers (i.e. dimers and trimers) much faster ( Figure 2C ). Consistent with faster nucleation and oligomer formation, pAb also showed increased aggregation into larger assemblies that were detected as smears at the upper parts of the gels. These data demonstrate that phosphorylation of Ab strongly promotes the formation of low-molecular weight oligomers and further aggregation into fibrils.
The formation of small soluble oligomers is associated with conformational changes resulting in increased b-sheet structure. We first measured the structural conversion of Ab monomers to aggregates by circular dichroism (CD) spectroscopy. At the start of the aggregation assay, the initial far-UV CD spectrum of npAb revealed the characteristic features of a mostly random coil state ( Figure 2D ). Incubation of npAb at 371C resulted in a prominent change in the CD spectrum. After incubation for 8 h, a CD profile was observed that is characteristic for extended b-sheet structure (broad negative peak at 210-220 nm; Figure 2D ). The initial CD spectrum of pAb was also as expected for an unfolded peptide. However, a characteristic pattern of extended b-sheet structure was clearly evident already after 2 h of incubation ( Figure 2E ), indicating that phosphorylation increases the propensity of Ab to adopt a b-sheet conformation and thereby promotes oligomerization. The combined in vitro data demonstrate that phosphorylation of Ab at Ser8 promotes the formation of oligomers that could increase aggregation.
Next, we compared the effect of pAb and npAb variants in nucleation-dependent polymerization. As expected, preformed oligomeric nuclei of npAb significantly reduced the lag period of fibril formation as compared with a non-seeded reaction ( Figure 2F ). More interestingly, oligomeric nuclei of pAb were much more efficient in promoting the aggregation reaction of npAb and almost completely eliminated the lag phase. These data demonstrate that oligomeric nuclei of pAb could efficiently seed the aggregation of npAb.
Detection of pAb in APP transgenic mice and human AD brain
To assess the phosphorylation of Ab and its effect on aggregation in vivo, we first generated phosphorylation-state-specific antibodies. Affinity purified antibody SA5434 was found to be highly specific for Ab phosphorylated at Ser8 (Supplementary Figure S3A) . We also tested several monoclonal antibodies for their binding to pAb and npAb. While antibody 82E1 detected both peptides, the antibody 6E10 was found to be highly specific for npAb (Supplementary Figure  S3A) . This antibody recognizes an epitope between amino acids 4 and 12 of the Ab domain that contains the identified phosphorylation site (Kim et al, 1988) . Notably, SA5434 did not react with full-length APP or its C-terminal fragment in brain extracts of transgenic mice, suggesting selective phosphorylation of Ab (Supplementary Figure S4) . SA5434 showed no reactivity with endogenous mouse APP in nontransgenic mice, further demonstrating the specificity of this antibody (Supplementary Figure S4) . The antibody also did not cross-react with other modified Ab species, including synthetic Ab phosphorylated at Ser26 or pyro Glu-modified Ab and with non-phosphorylated aggregates (Supplementary Figure S3B-D) .
We took advantage of the phosphorylation-state-specific antibodies to analyse the accumulation and deposition of pAb and npAb variants in the brains of APPswe/PS1DE9 double transgenic (tg) mice. At an age of 9 months, strong labelling of amyloid deposits with SA5434 was observed in the hippocampal region ( Figure 3A ). Most deposits also contained npAb as indicated by the co-staining with antibody 6E10. In individual plaques, however, a more pronounced reactivity of SA5434 in the core was evident, suggesting preferential deposition of pAb. Age-dependent analysis also revealed deposits of pAb already in the cortex of 2-month-old (2m) mice ( Figure 3B ). Ab deposition strongly increased with age and a large overlap of staining with antibodies SA5434 and 6E10 was found, indicating co-deposition of pAb together with npAb in extracellular plaques. Again, pAb appeared to be concentrated in the centre of individual plaques. We also detected small grain-like deposits selectively labelled by phospho-specific antibody SA5434 with little if any reactivity for 6E10 ( Figure 3B ). Such small deposits were not detected in non-transgenic mice (Supplementary Figure S5) . Additional double staining revealed that smaller SA5434 positive deposits of pAb were not labelled with the fluorescent Congo red analogue K114 (Crystal et al, 2003; LeVine, 2005) . In contrast, larger deposits showed a large overlap of SA5434 and K114 labelling (Supplementary Figure S5) . To further demonstrate pAb in brains of tg mice, we detected pAb and npAb by WB. Quantitative analysis revealed that about 20-25% of extracted monomeric Ab in 18m tg mice is in a phosphorylated state (Supplementary Figure S6) . The reactivity of monomeric Ab with antibody 6E10 markedly increased after treatment of brain homogenates with alkaline phosphatase, also indicating that about 20-30% of monomeric Ab is in a phosphorylated state in vivo at this age (Supplementary Figure S7) . Consistent with the immunohistochemical data, levels of pAb and npAb strongly increased with age ( Figure 3C ). Importantly, SA5434 showed strong reactivity with a smear in the upper regions of the gels, most likely representing oligomeric assemblies of Ab. These species were already detected at 2 months and became prominent at 6 months. At these ages, SA5434 detected very little monomeric Ab. In contrast, monoclonal antibody 6E10 readily detected monomeric Ab already in 6-months-old mice that strongly increased with age. As compared with antibody SA5434, the reactivity of antibody 6E10 with oligomeric Ab assemblies was much weaker and mainly detected in 12-and 18-monthsold animals ( Figure 3C ). Together, the specific detection of npAb and pAb in mouse brain indicates an enrichment of pAb in oligomeric assemblies and suggests that phosphorylation increased oligomerization of Ab in vivo.
Deposits containing pAb were also detected in senile plaques in human AD brain ( Figure 4A ; Supplementary Figure S8 ). Strong reactivity with SA5434 was observed in the core of neuritic plaques, while antibody 22C11 against the extracellular domain of APP selectively detected dystrophic neurites in close proximity to the amyloid core of the neuritic plaques ( Figure 4B ). Importantly, immunoprecipitation of Ab variants from distinct fractions of human AD brains revealed the selective accumulation of pAb in SDS-resistant oligomers ( Figure 4C ). Antibody SA5434 immunoprecipitated almost exclusively SDS stable dimers from fractions enriched in membrane-associated/intracellular Ab (TBS-TX extracts) or insoluble/fibrillar Ab (formic acid extracts), while both monomeric and dimeric pAb were isolated from fractions enriched in soluble extracellular Ab (TBS extract). In contrast, antibody AW8 detecting both pAb and npAb precipitated monomeric and dimeric forms from all three fractions. These data demonstrate that pAb is highly enriched in oligomeric assemblies of Ab in the human AD brain and support an increased aggregation of pAb in vivo. The selective detection of dimeric pAb upon extraction with formic acid also indicates a very high stability of these toxic assemblies in the human AD brain.
Increased accumulation and toxicity of pseudophosphorylated Ab in Drosophila
Drosophila expresses an APP-like protein, but the lack of b-secretase precludes generation of endogenous Ab-like peptides (Bilen and Bonini, 2005) . Thus, Drosophila models allow to study the aggregation of exogenous Ab variants in the absence of endogenous Ab peptides. First, we tested whether the substitution of Ser8 by an aspartate residue could mimic the aggregation promoting effect of phosphorylation. Importantly, pseudophosphorylated Ab S8D showed very similar aggregation characteristics like pAb in vitro and is, therefore, suitable to mimic pAb (Supplementary Figure S9) . To prevent potential effects of the mutation on Figure S4) . processing, we generated constructs encoding the Ab domain with signal sequence that drives selective expression of Ab variants in the secretory pathway (Crowther et al, 2005) . By quantitative real-time RT-PCR, we identified transgenic lines that express similar mRNA levels (Supplementary Figure S10A) . Consistent with previous results (Finelli et al, 2004; Crowther et al, 2005) , expression of Ab led to age-dependent degeneration of eyes ( Figure 5A) . Notably, the pseudophosphorylated Ab S8D variant led to strongly increased degeneration as compared with Ab WT (Figure 5A ; Supplementary Figure S10B ). The degeneration of eyes was associated with significant death of photoreceptor cells ( Figure 5B ), demonstrating increased toxicity of pseudophosphorylated Ab. Together, these data indicate that (pseudo)phosphorylated Ab exerts increased toxicity in vivo. We also detected Ab levels in corresponding eye extracts. Similar levels of Ab WT and Ab S8D were detected in extracts of 1-day-old flies, also indicating similar expression of both Ab variants ( Figure 5C ). Importantly, pseudophosphorylated Ab S8D accumulated to much higher levels as compared with Ab WT in 24-day-old flies ( Figure 5C ), strongly indicating that pseudophosphorylated Ab S8D showed increased aggregation and accumulation in vivo. Next, we also tested the effects of Ab WT and Ab Figure S8) . (B) Confocal double-label immunofluorescence photomicrographs of sections from the entorhinal cortex of a human AD brain stained with SA5434 (green) and 22C11 (red) against Ab and the APP ecto-domain, respectively. Cored neuritic pAb plaques are associated with swollen APP-positive dystrophic neurites. Scale bar represents 100 mm. (C) Detection of pAb in human AD brains. Brains of two AD cases (AD1 and AD2) or a control (Con.) were homogenized and sequentially extracted. Fractions enriched in extracellular soluble (TBS), membrane-associated (TBS-TX) and insoluble (formic acid) forms of Ab were immunoprecipitated with polyclonal antibodies AW8 or SA5434. Ab was then detected with monoclonal antibodies 2G3 (to Ab40) and 21F12 (to Ab42). Quantitative analysis by infrared imaging (as described in the Materials and methods section) revealed that about 46% in AD1 and 30% in AD2 of dimeric Ab in the TBS fraction is in a phosphorylated state.
S8D variants upon neuron-specific expression in the brain on its accumulation as well as on the climbing behaviour of flies, two additional parameters for aggregation and Ab-mediated neurotoxicity in vivo (Luheshi et al, 2007) . Confocal microscopic analysis of whole-mount brains revealed age-dependent accumulation of Ab peptides. As compared with Ab WT, Ab S8D showed highly increased accumulation ( Figure 6A ). Further, locomotor activity of Ab S8D flies shows an accelerated decrease compared with Ab WT or control flies during ageing ( Figure 6B ; Supplementary Movie S1), indicating a progressive age-dependent phenotype, which is caused by Ab peptide accumulation.
Discussion
Our data demonstrate that the phosphorylation of Ab increases its aggregation and toxicity. Since this post-translational modification can occur on WT Ab, these findings could Figure S10A) . Pseudophosphorylated Ab S8D showed strong accumulation at 24th dae as compared with Ab WT (right panel). Western blotting revealed that Ab WT was not phosphorylated in Drosophila (Supplementary Figure S9B) .
have very important implications to the pathogenesis of sporadic, late-onset forms of AD.
Increased aggregation and formation of neurotoxic oligomers of Ab appears to be critically involved in the initiation and progression of AD (Kayed et al, 2003; Forman et al, 2004; Tsai et al, 2004; Spires et al, 2005; Haass and Selkoe, 2007; Li et al, 2009) . This is strongly supported by the identification of mutations within the APP and PS genes that are major causes of EOAD. These mutations commonly cause increased production of Ab variants that show an increased tendency to form toxic aggregates (Chiti et al, 2003) . Especially, the C-terminal elongated Ab42 shows strongly increased aggregation as compared with the Ab40 variant. In addition, several FAD mutations are localized within or close to the b-turn region of Ab and could stabilize a b-sheet conformation of the peptide, thereby also promoting formation of neurotoxic aggregates. Recently, two mutations have been identified in the N-terminal region of Ab that also cause EOAD (Hori et al, 2007; Di et al, 2009) . This is particularly interesting, because previous studies suggested that this region of the peptide is highly flexible with very little secondary structure and has a minor role in aggregation (Murakami et al, 2002) . Moreover, a genetic mutation at position 2 of the Ab domain was recently identified to cause late-onset AD in a recessive fashion, indicating that the N-terminal part of Ab could have important roles in its aggregation and disease pathogenesis (Di et al, 2009) . A critical role of the N-terminal domain of Ab is supported by the finding that N-terminal truncation and formation of pyroglutamate at position 3 of the Ab peptide also strongly promotes aggregation and is an abundant species found in Ab deposits in the AD brain (Saido et al, 1995; Schilling et al, 2008) . It will now be interesting to assess the relative abundance of the different modified variants of Ab in human brains or CSF. Mass spectrometry would help to analyse the different modifications of Ab in vivo and could also provide definite proof whether they occur on individual peptides or probably in combination on the same molecule.
Protein fibrillization generally involves nucleation-dependent oligomerization as a rate-limiting step before rapid fibril growth (Rochet and Lansbury, 2000; Chiti et al, 2003) . That Ab plaque formation could be induced by inoculation of amyloid containing brain homogenates into monkeys or APP transgenic mice suggests that nucleation-dependent fibrillization also occurs in vivo (Walker et al, 2002; Meyer-Luehmann et al, 2006) . The rapid appearance of amyloid plaques within brains of tg mice further supports seeded growth of Ab fibrils in vivo (Meyer-Luehmann et al, 2008) . Our data demonstrate that phosphorylation at Ser8 promotes the nucleation of Ab and the formation of oligomers by increasing the propensity to adopt b-sheet conformation. This might be caused by a relative stabilization of the more extended peptide structure in pAb, possibly due to its higher negative charge density than the npAb. Moreover, ordering of disordered regions in the vicinity of the site of phosphorylation might lower the entropic cost for formation of ordered aggregates, contributing to an increased aggregation in case of pAb when compared with npAb. Thus, phosphorylated variants of Ab could trigger oligomerization and deposition of Ab during pathogenesis of sporadic AD (Figure 7 ). In agreement with this hypothesis, the nuclei of pAb were capable to promote aggregation of npAb in vitro much faster than nuclei of npAb ( Figure 2F) .
Importantly, the isolation of small soluble Ab assemblies from human AD brain strongly supported a critical role of pAb species in the formation of oligomeric assemblies in vivo. The precipitation with antibodies specifically detecting pAb revealed a selective enrichment in dimeric Ab variants, which are known to be highly neurotoxic (Roher et al, 1996; Shankar et al, 2008) . In addition, the selective detection of pAb in dimeric forms could also reflect increased stability of aggregates containing pAb. Thus, it will be also interesting to assess the stability of aggregates formed by pAb in comparison with that containing npAb. The importance of the present finding is further supported by the detection of pAb in neuritic plaques and SDS-stable dimers, which strongly argues in favour of a critical role of pAb in AD-related neurodegeneration (Roher et al, 1996; Shankar et al, 2008) . Furthermore, pAb also occurs in senile plaques of tg mice and recent studies have shown that such Ab deposits induce plaque-associated neuritic degeneration (Tsai et al, 2004; Spires et al, 2005) .
Drosophila is a valid model to study aggregation and toxicity of different Ab variants in vivo. Drosophila melanogaster has been utilized for the understanding of the molecular and cellular basis of AD pathogenesis (Bilen and Bonini, 2005) . Ab expressing fly models offer the possibility of studying Ab-induced toxicity and clearance, aggregation propensity and neurodegeneration, genetic and pharmacological screening system for developing therapeutics for AD. Since Drosophila lacks b-secretase activity, this model allows to assess Ab-mediated toxicity in the absence of endogenous Ab species (Finelli et al, 2004; Bilen and Bonini, 2005; Crowther et al, 2005; Iijima et al, 2008) . To mimic pAb, Ser8 was substituted by an aspartate residue, a strategy that has been successfully used to study the effect of protein phosphorylation (Fluhrer et al, 2004) . Importantly, the Ab S8D variant showed very similar aggregation characteristics like pAb in vitro, demonstrating the suitability of this strategy. We generated constructs that drive expression of Ab variants in the secretory pathway without APP, thereby ruling out any effects of the artificial mutation on the production of Ab peptides by altered proteolytic processing of its precursor. Pseudophosphorylated Ab S8D strongly promoted age-dependent degeneration of eyes associated with death of photoreceptor cells as compared with Ab WT, supporting increased toxicity of pAb in vivo. Moreover, the selective expression of Ab variants in brain neurons led to accelerated age-dependent climbing deficits in flies expressing Ab S8D, also demonstrating increased toxicity of pAb species in the brain. Although the exact mode of toxicity is unclear, the combined data demonstrate that mimicking phosphorylation of Ab strongly promotes age-dependent dysfunction of brain neurons. It will now be interesting to further dissect the underlying molecular pathways of pAb-mediated toxicity and its pathophysiological implications in more detail.
The presence of extracellular protein kinase activities has been widely described, but their biological relevance is poorly understood (Redegeld et al, 1999) . These kinases use extracellular ATP that is present in low nanomolar concentrations in the brain, but could increase locally to micromolar concentrations upon certain stimuli, including synaptic activity, inflammation and ischaemia in vivo (Melani et al, 2005; Gourine et al, 2007; Pedata et al, 2007) . Our combined data suggest that an extracellular PKA-like activity is involved in the phosphorylation of Ab. Interestingly, secretion of PKA has been demonstrated with different peripheral cell types (Cho et al, 2000a) . We here show that a PKA-like activity is also present in the conditioned media and/or the cell surface of primary mouse cortical neurons. Moreover, we identified a PKA-like activity in human CSF. These novel data strongly indicate that secretion of PKA occurs in the human brain. However, further studies are required to identify the molecular mechanism that underlie and regulate PKA secretion in the brain.
Because our data also indicate an important role of extracellular or cell surface-localized protein kinases in the pathogenesis of AD, these kinases could represent potential targets to decrease Ab aggregation and toxicity. Further, the detection of phosphorylated and npAb in biological fluids could also be explored for evaluation as biomarkers.
Materials and methods
Chemicals and antibodies
The following chemicals and antibodies were used: adenosine-3 0 , 5 0 -cyclic monophosphate (Biolog Life Science Institute, Germany), Congo red (AppliChem GmbH, Germany), K114, a fluorescent amyloid-specific dye (an analogue of Congo Red), Thioflavin T, Histone, H-89, PKI and KT5720 were purchased from Sigma (Germany) and Ab peptides were from Peptide Specialty Laboratory (Heidelberg, Germany). Monoclonal Ab antibodies 6E10 and 4G8 were purchased from Signet Laboratories, 82E1 antibody was from IBL Corporation (Japan), 2G3 and 21F12 antibodies, which specifically recognize Ab terminating at residues 40 and 42, were generous gift from Drs Peter Seubert and Dale Schenk (Elan Pharmaceuticals). AW8, a polyclonal anti-Ab antibody, was raised to aggregated synthetic Ab1-42 and fluorochrome-coupled antimouse IR800 antibody was from Rockland (Gilbertsville, PA). Monoclonal APP antibody 22C11 was purchased from Chemicon. The Cy-2 and Cy-3 fluorochromes were from Dianova (Germany) and Alexa Fluor 488 goat anti-mouse and Alexa Fluor 594 goat antirabbit secondary antibodies were purchased from Invitrogen (Germany). The PKA Ca-and Cb-specific antibodies were from Santa Cruz biotechnology.
Generation of phosphorylation-state-specific antibodies
The polyclonal phospho-specific antibody SA5434 was generated in rabbits by inoculation of synthetic peptide that represents amino acids 1-16 of Ab with a phosphoserine at position 8 coupled to keyhole limpet haemocyan (Eurogentec, Belgium). Phosphorylation-state-specific antibodies were isolated from the serum by double affinity purification against the phosphorylated and non- phosphorylated peptide. The specificity of the antibodies was characterized by ELISA and WB.
Phosphorylation assays
In vitro, in vivo and ex vivo phosphorylation of Ab using purified PKA, primary mouse neurons and human CSF are described in detail in Supplementary data.
Ab aggregation assays
Ab aggregation assays were carried out using synthetic npAb and pAb peptides and monitored by Thioflavin T, Congo Red, CD Spectroscopy and transmission electron microscopy. Further information is described in Supplementary data.
Transgenic mice, protein extraction and immunohistochemistry
The biochemical and immunohistochemical analyses of transgenic mice were carried out using APPswe/PS1DE9 double transgenic mice (Strain Name: B6C3-Tg, Jax Laboratories). Preparation of brain homogenates, protein extraction, WB, quantification and immunohistochemistry are described in detail in Supplementary data.
Analysis of human AD brain
Human AD brains were obtained from the University Hospital Bonn with the laws and the permission of the local ethical committees.
Immunofluorescence and confocal microscopy of human AD brain, human brain sample preparation and quantitation of Ab in human brain extracts by immunoprecipitation and western-blotting analysis are described in details in Supplementary data.
In vitro seeding assay
In vitro seeded aggregation of npAb was carried out using preaggregated npAb and pAb as seeds and aggregation was followed by ThT fluorescence measurement. The detailed procedures of all the above are described in Supplementary data.
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
